Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 592

1.

[A Case of Laparoscopic Local Resection of the Stomach for an Inflammatory Myofibroblastic Tumor].

Uno H, Takahara Y, Nishida T, Ohno T, Komatsu T.

Gan To Kagaku Ryoho. 2019 Dec;46(13):2054-2056. Japanese.

PMID:
32157057
2.

Synthesis and Aromaticity of Benzene-Fused Doubly N-Confused Porphyrins.

Uno H, Muramatsu K, Hiraoka S, Tahara H, Hirose M, Tamura E, Shiraishi T, Mack J, Kobayashi N, Mori S, Okujima T, Takase M.

Chemistry. 2020 Mar 8. doi: 10.1002/chem.202000339. [Epub ahead of print]

PMID:
32147874
3.

On the empirical choice of the time window for restricted mean survival time.

Tian L, Jin H, Uno H, Lu Y, Huang B, Anderson KM, Wei LJ.

Biometrics. 2020 Feb 15. doi: 10.1111/biom.13237. [Epub ahead of print]

PMID:
32061098
4.

Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes.

Uno H, Horiguchi M, Hassett MJ.

Oncologist. 2020 Feb;25(2):91-93. doi: 10.1634/theoncologist.2019-0464. Epub 2019 Nov 19. No abstract available.

5.

Synthesis of Both Enantiomers of Nine-Membered CF3 -Substituted Heterocycles Using a Single Chiral Ligand: Palladium-Catalyzed Decarboxylative Ring Expansion with Kinetic Resolution.

Uno H, Punna N, Tokunaga E, Shiro M, Shibata N.

Angew Chem Int Ed Engl. 2020 Jan 31. doi: 10.1002/anie.201915021. [Epub ahead of print]

PMID:
32003516
6.

Lifetime eurythermy by seasonally matched thermal performance of developmental stages in an annual aquatic insect.

Uno H, Stillman JH.

Oecologia. 2020 Mar;192(3):647-656. doi: 10.1007/s00442-020-04605-z. Epub 2020 Jan 27.

PMID:
31989318
7.

Chrysene-Bridged Porphyrin Tweezers: Chiral Receptors for Fullerenes.

Mori S, Kawamoto N, Uno H.

Chempluschem. 2019 Jun;84(6):686-693. doi: 10.1002/cplu.201900046. Epub 2019 Apr 4.

PMID:
31944003
8.

Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes.

Uno H, Horiguchi M, Hassett MJ.

Oncologist. 2019 Nov 19. pii: theoncologist.2019-0464. doi: 10.1634/theoncologist.2019-0464. [Epub ahead of print] No abstract available.

9.

Clinical Factors Associated with Urinary Tract Cancer in Individuals with Lynch Syndrome.

Wischhusen JW, Ukaegbu C, Dhingra TG, Uno H, Kastrinos F, Syngal S, Yurgelun MB.

Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):193-199. doi: 10.1158/1055-9965.EPI-19-0213. Epub 2019 Oct 15.

PMID:
31615790
10.

Goals of care discussions for patients with blood cancers: Association of person, place, and time with end-of-life care utilization.

Odejide OO, Uno H, Murillo A, Tulsky JA, Abel GA.

Cancer. 2020 Feb 1;126(3):515-522. doi: 10.1002/cncr.32549. Epub 2019 Oct 8.

PMID:
31593321
11.

Unrealistic parental expectations for cure in poor-prognosis childhood cancer.

Mack JW, Cronin AM, Uno H, Shusterman S, Twist CJ, Bagatell R, Rosenberg A, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park J, Cohn SL, Levine A, Taddei S, Diller LR.

Cancer. 2020 Jan 15;126(2):416-424. doi: 10.1002/cncr.32553. Epub 2019 Oct 4.

PMID:
31584705
12.

Synthesis and Isolation of Antiaromatic Expanded Azacoronene via Intramolecular Vilsmeier-Type Reaction.

Oki K, Takase M, Mori S, Uno H.

J Am Chem Soc. 2019 Oct 16;141(41):16255-16259. doi: 10.1021/jacs.9b09260. Epub 2019 Oct 3.

PMID:
31577141
13.

Patient-preferred outcomes measurement after post-mastectomy radiation therapy and immediate reconstruction.

Punglia RS, Ortiz Pimentel S, Cronin AM, Frank ES, Bellon JR, Abel GA, Uno H, Wong JS.

Breast J. 2020 Feb;26(2):319-321. doi: 10.1111/tbj.13592. Epub 2019 Sep 8. No abstract available.

PMID:
31495035
14.

Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease.

Hassett MJ, Banegas M, Uno H, Weng S, Cronin AM, O'Keeffe Rosetti M, Carroll NM, Hornbrook MC, Ritzwoller DP.

J Oncol Pract. 2019 Jul;15(7):e616-e627. doi: 10.1200/JOP.19.00004. Epub 2019 May 20.

15.

Hospitalization Risk During Chemotherapy for Advanced Cancer: Development and Validation of Risk Stratification Models Using Real-World Data.

Brooks GA, Uno H, Aiello Bowles EJ, Menter AR, O'Keeffe-Rosetti M, Tosteson ANA, Ritzwoller DP, Schrag D.

JCO Clin Cancer Inform. 2019 Apr;3:1-10. doi: 10.1200/CCI.18.00147.

16.

Performance of Cancer Recurrence Algorithms After Coding Scheme Switch From International Classification of Diseases 9th Revision to International Classification of Diseases 10th Revision.

Carroll NM, Ritzwoller DP, Banegas MP, O'Keeffe-Rosetti M, Cronin AM, Uno H, Hornbrook MC, Hassett MJ.

JCO Clin Cancer Inform. 2019 Mar;3:1-9. doi: 10.1200/CCI.18.00113.

17.

Effect of marijuana smoking on pulmonary disease in HIV-infected and uninfected men: a longitudinal cohort study.

Lorenz DR, Uno H, Wolinsky SM, Gabuzda D.

EClinicalMedicine. 2019 Jan;7:55-64. doi: 10.1016/j.eclinm.2019.01.003. Epub 2019 Jan 24.

18.

Synthesis and Redox Properties of Pyrrole- and Azulene-Fused Azacoronene.

Sasaki Y, Takase M, Okujima T, Mori S, Uno H.

Org Lett. 2019 Mar 15;21(6):1900-1903. doi: 10.1021/acs.orglett.9b00515. Epub 2019 Mar 5.

PMID:
30835482
19.

Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point.

Claggett B, Uno H, Wei LJ.

JAMA Surg. 2019 May 1;154(5):466-467. doi: 10.1001/jamasurg.2018.5852. No abstract available.

PMID:
30785628
20.

A cell-wall protein SRPP provides physiological integrity to the Arabidopsis seed.

Uno H, Tanaka-Takada N, Hattori M, Fukuda M, Maeshima M.

J Plant Res. 2019 Jan;132(1):145-154. doi: 10.1007/s10265-018-01083-6. Epub 2019 Jan 23.

PMID:
30673938
21.

Determining the Time of Cancer Recurrence Using Claims or Electronic Medical Record Data.

Uno H, Ritzwoller DP, Cronin AM, Carroll NM, Hornbrook MC, Hassett MJ.

JCO Clin Cancer Inform. 2018 Dec;2:1-10. doi: 10.1200/CCI.17.00163.

22.

Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.

Brooks GA, Austin AM, Uno H, Dragnev KH, Tosteson ANA, Schrag D.

JAMA Netw Open. 2018 Oct 5;1(6):e183023. doi: 10.1001/jamanetworkopen.2018.3023.

23.

Moving beyond the conventional stratified analysis to estimate an overall treatment efficacy with the data from a comparative randomized clinical study.

Tian L, Jiang F, Hasegawa T, Uno H, Pfeffer M, Wei LJ.

Stat Med. 2019 Mar 15;38(6):917-932. doi: 10.1002/sim.8015. Epub 2018 Oct 23.

PMID:
30352486
24.

Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection.

Aldersley J, Lorenz DR, Misra V, Uno H, Gabuzda D.

AIDS. 2019 Jan 27;33(1):145-152. doi: 10.1097/QAD.0000000000002059.

25.

Low T-cell subsets prior to development of virus-associated cancer in HIV-seronegative men who have sex with men.

Dutta A, Uno H, Lorenz DR, Wolinsky SM, Gabuzda D.

Cancer Causes Control. 2018 Nov;29(11):1131-1142. doi: 10.1007/s10552-018-1090-4. Epub 2018 Oct 12.

26.

How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?

Horiguchi M, Hassett MJ, Uno H.

Oncologist. 2019 Jul;24(7):867-871. doi: 10.1634/theoncologist.2018-0141. Epub 2018 Sep 10.

27.

Synthesis, Structures, and Properties of Core-Expanded Azacoronene Analogue: A Twisted π-System with Two N-Doped Heptagons.

Oki K, Takase M, Mori S, Shiotari A, Sugimoto Y, Ohara K, Okujima T, Uno H.

J Am Chem Soc. 2018 Aug 22;140(33):10430-10434. doi: 10.1021/jacs.8b06079. Epub 2018 Aug 7.

PMID:
30068084
28.

Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis.

Ritzwoller DP, Fishman PA, Banegas MP, Carroll NM, O'Keeffe-Rosetti M, Cronin AM, Uno H, Hornbrook MC, Hassett MJ.

Health Serv Res. 2018 Dec;53(6):5106-5128. doi: 10.1111/1475-6773.13014. Epub 2018 Jul 24.

29.

Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer.

Hassett MJ, Uno H, Cronin AM, Carroll NM, Hornbrook MC, Ritzwoller DP.

JNCI Cancer Spectr. 2018 Apr;2(2):pky024. doi: 10.1093/jncics/pky024. Epub 2018 Jun 28.

30.

Synthesis and Antimicrobial Activity of 2-Trifluoroacetonylbenzoxazole Ligands and Their Metal Complexes.

Watanabe G, Sekiya H, Tamai E, Saijo R, Uno H, Mori S, Tanaka T, Maki J, Kawase M.

Chem Pharm Bull (Tokyo). 2018;66(7):732-740. doi: 10.1248/cpb.c18-00158.

31.

Estrogen-receptor status and risk of contralateral breast cancer following DCIS.

Stout NK, Cronin AM, Uno H, Ozanne EM, Hassett MJ, Frank ES, Greenberg CC, Punglia RS.

Breast Cancer Res Treat. 2018 Oct;171(3):777-781. doi: 10.1007/s10549-018-4860-5. Epub 2018 Jun 26.

PMID:
29946862
32.

Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis.

Uno H, Tian L, Wei LJ.

JAMA Oncol. 2018 Aug 1;4(8):1137-1138. doi: 10.1001/jamaoncol.2018.1087. No abstract available.

33.

Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.

Uno H, Kim DH, Wei LJ.

JAMA Oncol. 2018 Aug 1;4(8):1135-1136. doi: 10.1001/jamaoncol.2018.0881. No abstract available.

PMID:
29902302
34.

Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm.

Ritzwoller DP, Hassett MJ, Uno H, Cronin AM, Carroll NM, Hornbrook MC, Kushi LC.

J Natl Cancer Inst. 2018 Mar 1;110(3):273-281. doi: 10.1093/jnci/djx200.

35.

Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study.

Horiguchi M, Tian L, Uno H, Cheng S, Kim DH, Schrag D, Wei LJ.

JAMA Oncol. 2018 Jun 1;4(6):881-882. doi: 10.1001/jamaoncol.2018.0518. No abstract available.

36.

Contact dermatitis to Dermabond Advance®.

Kanazawa A, Uno H, Nakada T, Shaw DW, Maibach HI.

Australas J Dermatol. 2019 Feb;60(1):63-64. doi: 10.1111/ajd.12843. Epub 2018 May 11. No abstract available.

PMID:
29749093
37.

Access to benzo-fused nine-membered heterocyclic alkenes with a trifluoromethyl carbinol moiety via a double decarboxylative formal ring-expansion process under palladium catalysis.

Das P, Gondo S, Nagender P, Uno H, Tokunaga E, Shibata N.

Chem Sci. 2018 Feb 23;9(13):3276-3281. doi: 10.1039/c7sc05447e. eCollection 2018 Apr 7.

38.

Decision on performing interim analysis for comparative clinical trials.

Pak K, Jacobus S, Uno H.

Contemp Clin Trials Commun. 2017 Aug 16;7:224-230. doi: 10.1016/j.conctc.2017.08.001. eCollection 2017 Sep.

39.

A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials.

Horiguchi M, Cronin AM, Takeuchi M, Uno H.

Stat Med. 2018 Jul 10;37(15):2307-2320. doi: 10.1002/sim.7661. Epub 2018 Apr 22.

PMID:
29682762
40.

Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.

Mukerji SS, Misra V, Lorenz DR, Uno H, Morgello S, Franklin D, Ellis RJ, Letendre S, Gabuzda D.

Clin Infect Dis. 2018 Sep 28;67(8):1182-1190. doi: 10.1093/cid/ciy267.

41.

Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis.

Uno H, Claggett B, Tian L, Fu H, Huang B, Kim DH, Wei LJ.

Ann Oncol. 2018 May 1;29(5):1092-1094. doi: 10.1093/annonc/mdy109. No abstract available.

42.

Commentary: PREMM5 threshold of 2.5% is recommended to improve identification of PMS2 carriers.

Kastrinos F, Uno H, Syngal S.

Fam Cancer. 2018 Oct;17(4):567. doi: 10.1007/s10689-018-0074-6. No abstract available.

PMID:
29380099
43.

Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer.

Horiguchi M, Uno H, Wei LJ.

J Clin Oncol. 2018 Mar 10;36(8):825-826. doi: 10.1200/JCO.2017.75.9829. Epub 2018 Jan 26. No abstract available.

PMID:
29373099
44.

Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors.

Fang X, Uno H, Wei LJ.

JAMA Oncol. 2018 May 1;4(5):743. doi: 10.1001/jamaoncol.2017.3983. No abstract available.

PMID:
29372245
45.

Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer.

Uno H, Hassett MJ, Wei LJ.

JAMA. 2018 Jan 16;319(3):306. doi: 10.1001/jama.2017.18312. No abstract available.

PMID:
29340668
46.

Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.

Horiguchi M, Uno H, Wei LJ.

J Clin Oncol. 2018 Mar 1;36(7):720-721. doi: 10.1200/JCO.2017.76.0983. Epub 2018 Jan 16. No abstract available.

PMID:
29337638
47.

Interactive or static reports to guide clinical interpretation of cancer genomics.

Gray SW, Gagan J, Cerami E, Cronin AM, Uno H, Oliver N, Lowenstein C, Lederman R, Revette A, Suarez A, Lee C, Bryan J, Sholl L, Van Allen EM.

J Am Med Inform Assoc. 2018 May 1;25(5):458-464. doi: 10.1093/jamia/ocx150.

48.

[A CASE OF A 7-YEAR-OLD GIRL WITH ANAPHYLAXIS CAUSED BY PECTIN IN ALBEDO OF CITRUS UNSHIU BUT NOT BY THE FRUIT ITSELF].

Uno H, Sekimoto H, Kitamura T.

Arerugi. 2017;66(10):1244-1247. doi: 10.15036/arerugi.66.1244. Japanese.

PMID:
29249759
49.

Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer.

Hasegawa T, Uno H, Wei LJ.

JAMA Oncol. 2018 Apr 1;4(4):585. doi: 10.1001/jamaoncol.2017.0487. No abstract available.

PMID:
29192309
50.

Poor performance of clinical prediction models: the harm of commonly applied methods.

Steyerberg EW, Uno H, Ioannidis JPA, van Calster B; Collaborators.

J Clin Epidemiol. 2018 Jun;98:133-143. doi: 10.1016/j.jclinepi.2017.11.013. Epub 2017 Nov 24.

PMID:
29174118

Supplemental Content

Support Center